| Literature DB >> 27326244 |
Masahiko Sakoda1, Shinichi Ueno2, Satoshi Iino1, Kiyokazu Hiwatashi1, Koji Minami1, Yota Kawasaki1, Hiroshi Kurahara1, Yuko Mataki1, Kosei Maemura1, Hiroyuki Shinchi3, Shoji Natsugoe1.
Abstract
BACKGROUND: It has been reported that anatomical resection of the liver may be preferred for primary hepatocellular carcinoma (HCC), and is at least recommended for systematic removal of a segment confined by tumor-bearing portal tributaries. However, nonanatomical resection (NAR) is often selected because of the patient's background, impairment of liver function, and tumor factors. The aims of the present study were to retrospectively compare the recurrence-free survival (RFS) rates for cases of partial resection (PR) and for small anatomical resection (SAR), which is regarded as NAR for primary HCC with impaired liver function. PATIENTS AND METHODS: So-called NAR was performed for a primary and solitary (≤ 5cm) HCC in 47 patients; the patients were classified into PR (n=25) and SAR (n=22) groups. Clinicopathological factors, survival data, and recurrence patterns were compared between groups.Entities:
Keywords: anatomical resection; hepatectomy; hepatocellular carcinoma; intrahepatic recurrence; liver cirrhosis; nonanatomical resection
Year: 2016 PMID: 27326244 PMCID: PMC4911868 DOI: 10.7150/jca.15174
Source DB: PubMed Journal: J Cancer ISSN: 1837-9664 Impact factor: 4.207
Figure 1Flow diagram of therapeutic methods for patients with a primary, solitary and ≤ 5cm HCC.
Figure 23D images based on multidetector CT. (A) The 3rd order portal vein branch (arrowhead) for staining and dissection in Couinaud's segmentectomy, same as subsegmentectomy under Japanese general guidelines, and the 4th order portal vein branch (arrow) for staining and dissection in SAR of this study. (B) The 3rd order portal vein branches (arrowhead and arrow) for staining and dissection in Couinaud's segmentectomy, and one of the 3rd order portal vein branches (arrow) for staining and dissection in SAR of this study. PX: segmental portal vein branch of segment X; MHV: middle hepatic vein; RHV: right hepatic vein; IVC: inferior vena cava.
Preoperative characteristics of the entire study population
| Variables | PR | SAR | |
|---|---|---|---|
| Age (years) | 68 (41-79) | 72 (53-81) | 0.181 |
| Gender, Male / Female | 19 / 6 | 12 / 10 | 0.212 |
| BMI (kg/m2) | 24.0 (18.4-31.8) | 23.6 (19.7-27.8) | 0.674 |
| Diabetes mellitus, yes / no | 5 / 20 | 7 / 15 | 0.549 |
| Alcohol consumption, yes / no | 10 / 15 | 3 / 19 | 0.090 |
| HBsAg, positive / negative | 3 / 22 | 4 / 18 | 0.848 |
| Anti-HCV-Ab, positive /negative | 18 / 7 | 10 / 12 | 0.119 |
| Child-Pugh classification, A / B | 21 / 4 | 22 / 0 | 0.147 |
| Liver damagea, A / B | 19 / 6 | 17 / 5 | >.9999 |
| ICGR15 (%) | 20.1 (1.2-48) | 17.5 (4.3-58) | 0.434 |
| Platelets (x104/μL) | 13.4 (5.4-25.3) | 14.6 (6.3-31.7) | 0.559 |
| Prothrombin time (%) | 91 (60-116) | 95 (86-106) | 0.150 |
| Albimin (g/dL) | 3.9 (3.0-4.8) | 3.8 (2.5-4.5) | 0.394 |
| Total bilirubin (mg/dL ) | 0.9 (0.4-1.6) | 0.8 (0.3-1.7) | 0.286 |
| AST (IU/L) | 47 (21-97) | 38 (21-75) | 0.075 |
| ALT (IU/L) | 45 (13-89) | 35 (11-114) | 0.130 |
| AFP (ng/ml)b | 14 (2-1087) | 8 (2.2-37537) | 0.277 |
| DCP (mAU/ml)b | 29 (11-7849) | 24 (11-1951) | 0.594 |
a According to the criteria of the Liver Cancer study Group of Japan [ref. 7]
b Median (range)
BMI: body mass index; ICGR15: indocyanine green retention rate at 15 min.
Perioperative variables and tumor factors
| Variables | PR | SAR | |
|---|---|---|---|
| Operative variables | |||
| Main location of the tumor, no. | |||
| Segment I/II/III/IV/V/VI/VII/VIII | 0/1/2/2/5/7/1/7 | 0/0/1/0/5/12/2/2 | 0.269 |
| Operative time (min)a | 255 (141-498) | 312 (228-619) | 0.009 |
| Intraoperative blood loss (ml)a | 220 (15-3425) | 720 (5-2480) | 0.298 |
| Postoperative morbidity | |||
| Clavien grade 1 or more, no. (%) | 7 (28) | 7 (32) | >.9999 |
| Clavien grade 3 or more, no. (%) | 2 (8) | 2 (9.1) | >.9999 |
| Mortality, no. (%) | 1 (4) | 0 (0) | >.9999 |
| Postoperative hospitalization (days) | 14 (6-39) | 13 (9-24) | 0.561 |
| Tumor factors | |||
| Size (mm) | 22 (8-50) | 25 (10-45) | 0.349 |
| Gross classification | |||
| Boundary typeb / Non-boundary typec | 19 / 6 | 18 / 4 | 0.892 |
| Microscopic pv invasion positive, no. (%) | 2 (8) | 2 (9.1) | >.9999 |
| Microscopic hv invasion positive, no. (%) | 1 (4) | 1(4.5) | >.9999 |
| Tumor differentiation | 6 / 17 / 2 | 10 / 10 / 2 | 0.268 |
| Surgical margin (mm) | 4.0 (0-14) | 9.8 (1.0-35) | 0.001 |
| TNM staged, I / II / III | 11 / 11 / 3 | 8 / 10 / 4 | 0.789 |
a Median (range)
b Boundary type: small nodular type with indistinct margin and simple nodular type
c Non-boundary type: simple nodular type with extranodular growth and confluent multinodular type
d According to the criteria of the Liver Cancer study Group of Japan [ref. 7]
pv: portal vein; hv: hepatic vein.
Figure 3(A) Recurrence-free survival of SAR group and PR group. (B) Cumulative overall survival of SAR group and PR group.
Recurrence patterns of HCC in PR and SAR
| Variables | PR | SAR | |
|---|---|---|---|
| Number of recurrence tumor, no. (%) | 0.505 | ||
| Solitary | 7 (28.0) | 1 (4.5) | |
| Multiple | 7 (28.0) | 4 (18.2) | |
| Site of recurrence, no. (%) | |||
| Extrahepatic recurrence | 1 (4.0) | 1 (4.5) | >.9999 |
| Intrahepatic recurrence | 14 (56.0) | 4 (18.2) | 0.018 |
| Pattern of intrahepatic recurrence, no. (%) | 0.455 | ||
| In the same segment as the initial tumor | 3 (12.0) | 1 (4.5) | |
| In a different segment from the initial tumor | 8 (32.0) | 1 (4.5) | |
| Multisegmental recurrence | 3 (12.0) | 2 (9.1) | |
| Location of the recurrence in the same segment | |||
| Segment V / VI / VII / VIII | 1 / 1 / 0 / 1 | 0 / 1 / 0 / 0 | >.9999 |
Risk factors for RFS after operation by univariate and multivariate analyses
| Variables | Univariate | Multivariate | ||
|---|---|---|---|---|
| Hazard ratio (95% CI) | P | Hazard ratio (95% CI) | P | |
| Age (≥70 years) | 1.56 (0.61-3.97) | 0.355 | ||
| Gender (male) | 0.92 (0.36-2.36) | 0.868 | ||
| BMI (≥24 kg/m2) | 0.96 (0.39-2.36) | 0.923 | ||
| Diabetes mellitus (yes) | 1.20 (0.40-3.61) | 0.752 | ||
| Alcohol consumption (yes) | 2.37 (0.92-6.10) | 0.074 | ||
| HBsAg (positive) | 0.20 (0.03-1.51) | 0.119 | ||
| Anti-HCV-Ab (positive) | 4.27 (1.24-14.7) | 0.022 | 2.42 (0.54-10.75) | 0.248 |
| Child-Pugh classification (B) | 2.54 (0.71-9.09) | 0.152 | ||
| Liver damagea (B) | 2.16 (0.81-5.71) | 0.124 | ||
| ICGR15 (≥18 %) | 2.26 (0.85-5.96) | 0.101 | ||
| Platelets (<12 x104/μL) | 2.34 (0.89-6.17) | 0.085 | ||
| Prothrombin time (<90 %) | 2.05 (0.83-5.08) | 0.119 | ||
| Albimin (<4.0 g/dL) | 1.89 (0.74-4.85) | 0.184 | ||
| Total bilirubin (≥0.8 mg/dL ) | 1.07 (0.38-2.98) | 0.897 | ||
| AST (≥38 IU/L) | 3.64 (1.30-10.2) | 0.014 | 1.82 (0.37-8.90) | 0.459 |
| ALT (≥32 IU/L) | 2.94 (1.15-7.53) | 0.025 | 0.84 (0.19-3.70) | 0.817 |
| AFP (≥10 ng/ml) | 3.01 (1.16-7.80) | 0.024 | 1.93 (0.60-6.17) | 0.268 |
| DCP (≥27 mAU/ml) | 2.21 (0.84-5.78) | 0.107 | ||
| Operative procedure (PR) | 3.32 (1.17-9.43) | 0.024 | 3.36 (1.10-10.20) | 0.033 |
| Operative time (≥280 min) | 0.81 (0.33-2.00) | 0.647 | ||
| Intraoperative blood loss (≥450 ml) | 0.65 (0.25-1.64) | 0.359 | ||
| Surgical margin (<5 mm) | 1.76 (0.71-4.33) | 0.222 | ||
| Postoperative morbidity | 0.78 (0.10-5.85) | 0.809 | ||
| Tumor size (≥2.0 cm) | 0.92 (0.36-2.35) | 0.860 | ||
| Gross classification | 0.84 (0.25-2.90) | 0.788 | ||
| Microscopic pv invasion (positive) | 1.69 (0.38-7.46) | 0.490 | ||
| Microscopic hv invasion (positive) | 2.97 (0.65-13.5) | 0.158 | ||
| Tumor differentiation (poorly) | 2.24 (0.29-17.2) | 0.440 | ||
| TNM stagea (III) | 1.18 (0.34-4.06) | 0.799 | ||
a According to the criteria of the Liver Cancer study Group of Japan [ref. 7]
b Non-boundary type: simple nodular type with extranodular growth and confluent multinodular type
RFS: recurrence-free survival; CI: confidence interval.